Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)
Mélanie Casile, Gilles Albrand, Clément Lahaye, Benjamin Lebecque, Joévin Besombes, Céline Bourgne, Bruno Pereira, Sandrine Saugues, Caroline Jamot, Eric Hermet, Marc G. Berger
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCombustion and flame dynamics · Advanced Combustion Engine Technologies · Radiative Heat Transfer Studies
Correction: BMC Cancer 24, 661 (2024)
10.1186/s12885-024-12415-2.
Following publication of the original article [1], it was reported that the third author, Clément Lahaye, was erroneously omitted from the author group. Clément Lahaye is affiliated with Unité mobile de Gériatrie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
The author group above has been updated and the original article [1] has been corrected.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Casile M Albrand G Lahaye C Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)BMC Cancer 20242466110.1186/s 12885-024-12415-238816821 PMC 11140958 · doi ↗ · pubmed ↗